Kopran Ltd
KOPRAN
Company Profile
Business description
Kopran Ltd is an Indian based pharmaceutical company. It is engaged in manufacturing of Formulation (Finished Dosage Form) and Active Pharmaceutical Ingredients (API) i.e., Pharmaceuticals. It manufactures dosage forms including, tablets, capsules, dry powder, suspension, and injectables. Some of its product range includes antibiotics, cardiovascular, anti-diabetes, respiratory, pain management, and gastrointestinal. Geographically, it has a presence in India; South Africa; Ethiopia; Zambia; Egypt; Jordan and Rest of World.
Contact
Dr. E. Moses Road
1076, Parijat House
Worli
MumbaiMH400 018
INDT: +91 2243661111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
1,024
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.00 | 22.40 | -0.25% |
| CAC 40 | 8,227.32 | 70.89 | 0.87% |
| DAX 40 | 24,155.45 | 39.45 | -0.16% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,457.01 | 19.45 | -0.19% |
| HKSE | 25,915.20 | 248.04 | -0.95% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,608.10 | 467.87 | 0.79% |
| NZX 50 Index | 12,889.71 | 4.78 | 0.04% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,775.00 | 23.60 | -0.27% |
| SSE Composite Index | 4,093.25 | 13.01 | -0.32% |